Michael P Digiovanna

Summary

Affiliation: Yale University
Country: USA

Publications

  1. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
  2. doi request reprint Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter
    Carla J Christy
    Department of Surgery, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Ann Surg Oncol 16:697-702. 2009
  3. doi request reprint Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
    Ashok K Chakraborty
    Departments of Internal Medicine Section of Medical Oncology and Pharmacology, and the Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, Room WWW217, New Haven, CT 06510, USA
    Breast Cancer Res Treat 120:327-35. 2010
  4. pmc Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
    Debbie C Koay
    Department of Internal Medicine Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven Hospital, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Breast Cancer Res 12:R62. 2010
  5. ncbi request reprint Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates
    Michael P Digiovanna
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer Res 62:6667-73. 2002
  6. ncbi request reprint Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
    Maysa M Abu-Khalaf
    Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, CT 06520 8032, USA
    Breast Cancer Res Treat 104:341-9. 2007
  7. doi request reprint Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA
    Breast Cancer Res Treat 150:157-67. 2015
  8. doi request reprint Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer
    Ashok K Chakraborty
    Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA
    Cancer Res 68:1538-45. 2008
  9. ncbi request reprint In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer
    Chun Xia Wang
    Department of Internal Medicine Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, Room NSB288, 06510, New Haven, CT 06510, USA
    Breast Cancer Res Treat 92:251-63. 2005
  10. ncbi request reprint Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients
    Michael P Digiovanna
    Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:1152-60. 2005

Collaborators

Detail Information

Publications22

  1. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  2. doi request reprint Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter
    Carla J Christy
    Department of Surgery, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Ann Surg Oncol 16:697-702. 2009
    ..The goal of this study is to assess the effect of preoperative chemotherapy on breast cancers between 2 and 4 cm diameter...
  3. doi request reprint Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
    Ashok K Chakraborty
    Departments of Internal Medicine Section of Medical Oncology and Pharmacology, and the Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, Room WWW217, New Haven, CT 06510, USA
    Breast Cancer Res Treat 120:327-35. 2010
    ..The drug combination synergistically inhibited ER and IGF1R activity. Such combinations may be useful therapy for breast cancer...
  4. pmc Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
    Debbie C Koay
    Department of Internal Medicine Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven Hospital, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Breast Cancer Res 12:R62. 2010
    ..Retinoids inhibit breast cancer growth, and modulate signaling by HER2 and ER. We hypothesized that treatment with retinoids and simultaneous targeting of HER2 and/or ER may have enhanced anti-tumor effects...
  5. ncbi request reprint Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates
    Michael P Digiovanna
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer Res 62:6667-73. 2002
    ....
  6. ncbi request reprint Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
    Maysa M Abu-Khalaf
    Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, CT 06520 8032, USA
    Breast Cancer Res Treat 104:341-9. 2007
    ....
  7. doi request reprint Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA
    Breast Cancer Res Treat 150:157-67. 2015
    ..mTOR inhibition may overcome resistance to trastuzumab in some HER2-positive tumors. ..
  8. doi request reprint Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer
    Ashok K Chakraborty
    Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA
    Cancer Res 68:1538-45. 2008
    ..Hence, such drug combinations may be clinically useful and may be beneficial even in tumors in which single drugs are inactive, as exemplified by the effect of the HER2/IGFIR inhibitor combination in HER2 nonoverexpressing MCF7 cells...
  9. ncbi request reprint In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer
    Chun Xia Wang
    Department of Internal Medicine Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, Room NSB288, 06510, New Haven, CT 06510, USA
    Breast Cancer Res Treat 92:251-63. 2005
    ..Our results indicate that combined targeting of both peptide growth factor receptors and ERalpha represents a promising breast cancer treatment strategy...
  10. ncbi request reprint Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients
    Michael P Digiovanna
    Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:1152-60. 2005
    ..To examine the relationship of epidermal growth factor receptor (EGFR) expression to ErbB-2 signaling activity in breast cancer and the impact that this interaction has on the prognosis of patients with early-stage breast cancer...
  11. doi request reprint Production of antibodies that recognize specific tyrosine-phosphorylated peptides
    Michael P Digiovanna
    Yale University School of Medicine, New Haven, Connecticut, USA
    Curr Protoc Immunol . 2002
    ..Support protocols are provided for the coupling of peptides and phosphotyrosine to an affinity matrix (Affi-Gel 10); BSA-agarose affinity matrix is commercially available...
  12. ncbi request reprint Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
    Athanassios Argiris
    Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 10:1409-20. 2004
    ..This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments...
  13. doi request reprint Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer
    Jason R Brown
    Department of Pathology, Yale Pathology Tissue Services, Yale University Medical School, New Haven, CT, USA
    Lab Invest 94:98-106. 2014
    ..Measurement of Ki-67 expression by objective quantitative methods shows increased Ki-67 levels are an independent predictor of response to neoadjuvant chemotherapy. ..
  14. doi request reprint Breast sentinel lymph node dissection before preoperative chemotherapy
    Baiba J Grube
    Departmentof Surgery, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Arch Surg 143:692-9; discussion 699-700. 2008
    ..Timing of sentinel lymph node dissection (SLND), before or after preoperative chemotherapy (PC), for breast cancer is controversial...
  15. doi request reprint Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer
    Taiga Nishihori
    Department of Internal Medicine, Medical Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT, USA
    Clin Breast Cancer 8:362-5. 2008
    ..Aromatase inhibitors might accentuate the occurrence of CTS and potentially other nerve entrapment syndromes, and a more systematic approach should be used to better understand the clinical significance and incidence of these symptoms...
  16. doi request reprint In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
    Ashok K Chakraborty
    Departments of Internal Medicine Section of Medical Oncology and Pharmacology, and the Yale Cancer Center, Yale University School of Medicine, 300 George Street, Suite 120, New Haven, CT, 06510, USA
    Breast Cancer Res Treat 152:533-44. 2015
    ....
  17. doi request reprint Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors
    Maysa M Abu-Khalaf
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
    Cancer 121:1817-26. 2015
    ..The optimal weekly oral dose of sirolimus and intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) were evaluated...
  18. doi request reprint Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
    Sarah S Mougalian
    Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut
    Cancer 121:2544-52. 2015
    ..The objective of the current study was to assess temporal trends in NAC use and to examine what clinical, demographic, and treatment site characteristics influence its use...
  19. ncbi request reprint Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models
    Ashok K Chakraborty
    Departments of Internal Medicine Section of Medical Oncology and Pharmacology, and the Yale Cancer Center Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT, U S A
    Anticancer Res 35:1243-50. 2015
    ..Herein we describe the effects of co-targeting in models of differing HER2 overexpression status (MCF7 HER2-normal/ER+, BT474 HER2-overexpressing/ER+)...
  20. pmc Self-management and transitions in women with advanced breast cancer
    Dena Schulman-Green
    Yale School of Nursing, New Haven, Connecticut, USA
    J Pain Symptom Manage 42:517-25. 2011
    ..Little is known about individuals' experiences with self-management, especially during transitions...
  21. doi request reprint Production of antibodies that recognize specific tyrosine-phosphorylated peptides
    Michael P Digiovanna
    Yale University School of Medicine, New Haven, Connecticut, USA
    Curr Protoc Cell Biol . 2002
    ..This unit describes the methods used to produce and screen monoclonal and polyclonal antibodies for specificity for only the phosphorylated state of a peptide...
  22. ncbi request reprint Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma
    Atif J Khan
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520 8040, USA
    Clin Cancer Res 8:540-8. 2002
    ....